Form 8.3 - Xeris Pharmaceuticals, Inc.

LONDON--(BUSINESS WIRE)-- 

Ap19

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1. KEY INFORMATION

Name of person dealing (Note 1)	Millennium International Management LP
Company dealt in	Xeris Pharmaceuticals, Inc.
Class of relevant security to which the dealings being disclosed relate (Note 2)	US98422L1070
Date of dealing	28^th June 2021

1. INTERESTS AND SHORT POSITIONS

1. Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities	599,475 (0.903%)		44,038 (0.066%)
(2) Derivatives (other than options)	-		-
(3) Options and agreements to purchase/sell	-		-
Total	599,475 (0.903%)		44,038 (0.066%)

1. Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

Ap20

1. DEALINGS (Note 4)

1. Purchases and sales

Purchase/sale	Number of relevant securities	Price per unit (Note 5) (USD)
Purchase	600	4.48
Purchase	800	4.48
Purchase	121,243	4.48
Purchase	12,631	4.48
Purchase	1,529	4.48
Purchase	452,986	4.48
Purchase	241,251	4.48
Purchase	14,025	4.48
Sale	505,342	4.48
Sale	900	4.69
Sale	200	4.70
Sale	4,193	4.74
Sale	8,000	4.68
Sale	250	4.67
Sale	1,020	4.61
Sale	800	4.75
Sale	231	4.66
Sale	3,455	4.60
Sale	3,928	4.63
Sale	6,422	4.58
Sale	741	4.56
Sale	364	4.52
Sale	6,726	4.57
Sale	2,242	4.59
Sale	1,972	4.62
Sale	100	4.55
Sale	14,930	4.47
Sale	1,000	4.53
Sale	4,300	4.54
Sale	281	4.46
Sale	4,035	4.50
Purchase	329	4.48
Sale	555,115	4.48
Sale	400	4.73
Sale	125	4.64
Sale	3	4.70
Sale	924	4.68
Sale	300	4.67
Sale	619	4.61
Sale	4,384	4.60
Sale	26,922	4.58
Sale	2,558	4.56
Sale	7,929	4.52
Sale	2,340	4.57
Sale	3,637	4.59
Sale	200	4.62
Sale	2,658	4.55
Sale	900	4.49
Purchase	1,461	4.47
Sale	2,792	4.53
Sale	300	4.54
Sale	95	4.78
Purchase	60	4.46
Sale	2,216	4.46
Sale	7,800	4.51
Sale	300	4.44
Purchase	530	4.48
Sale	18,674	4.48
Purchase	1	4.71
Sale	290	4.71
Sale	21	4.55
Purchase	14,995	4.48
Purchase	15,008	4.48
Purchase	15,857	4.48
Purchase	177,013	4.48
Purchase	3,120	4.48

1. Derivatives transactions (other than options transactions)

Product name, e.g. CFD

Nature of transaction (Note 6)

Number of relevant securities (Note 7)

Price per unit (GBP) (Note 5)

1. Exercising

Product name, e.g. call option

Number of securities

Exercise price per unit (Note 5)

1. Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction (Note 8)

Details

Price per unit (if applicable) (Note 5)

Ap21

2. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

None.

Is a Supplemental Form 8 attached? (Note 9) NO

Date of disclosure	29^th June 2021
Contact name	Milos Naumovic
Telephone number	[phone]
If a connected EFM, name of offeree/offeror with which connected
If a connected EFM, state nature of connection (Note 10)